|

PROMOTE Study: Prediction of Response Of HorMOnal Treatment in Advanced and Recurrent Endometrial Cancer

RECRUITINGSponsored by Radboud University Medical Center
Actively Recruiting
SponsorRadboud University Medical Center
Started2022-10-15
Est. completion2026-10-15
Eligibility
Age18 Years – 110 Years
SexFEMALE
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT03621904

Summary

The PROMOTE study aims at optimising use of hormonal therapy in advanced stage and recurrent endometrial cancer analysing tumor tissue taken before start of hormonal therapy

Eligibility

Age: 18 Years – 110 YearsSex: FEMALEHealthy volunteers accepted
Inclusion Criteria:

* Advanced stage (FIGO stage III and IV) and recurrent endometrial cancer
* All histologic types of endometrial carcinoma
* Planned treatment with any type of hormonal therapy
* Biopsy taken within 120 days prior to start of hormonal therapy with no intercurrent therapy between biopsy and start of hormonal therapy.

Exclusion Criteria:

* Adjuvant hormonal therapy started following complete resection of endometrial carcinoma
* Synchronous use of hormonal therapy for other indications
* Endometrial sarcoma or endometrial stroma cell sarcoma

Conditions4

CancerEndometrial Cancer RecurrentEndometrial Cancer Stage IIIEndometrial Cancer Stage IV

Interventions1

Hormonal Antineoplastics

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.